Cell Therapy for Unmet Medical Needs

Asterias Biotherapeutics is a leading biotechnology company in the emerging field of regenerative medicine. The company’s proprietary cell therapy programs are based on its immunotherapy and pluripotent stem cell platform technologies. Asterias is presently focused on advancing three clinical-stage programs which have the potential to address areas of very high unmet medical need in the fields of oncology and neurology. We are traded on the NYSE MKT under the ticker symbol AST.

Clinical Trials

Spinal Cord Injury Research Study

Asterias is conducting a clinical study to evaluate the safety and activity of AST-OPC1 in patients with complete cervical spinal cord injury. AST-OPC1 consists of cells known as oligodendrocyte progenitor cells (OPCs). The purpose of the study is to evaluate the safety of AST-OPC1 administered once between 14 and 30 days after injury. Researchers will also assess the impact on patient hand and arm function.

Learn More

Investors

Stock Quote

AST

Investor Presentations

Asterias Biotherapeutics to Report First Quarter Results
To view the webcast please click here

View More